NTRA - Natera Inc. (NTRA) Q1 2024 Earnings Call Transcript

2024-05-09 23:28:04 ET

Natera, Inc. (NTRA)

Q1 2024 Earnings Conference Call

May 09, 2024 04:30 PM ET

Company Participants

Mike Brophy - Chief Financial Officer

Steve Chapman - Chief Executive Officer

Solomon Moshkevich - President, Clinical Diagnostics

Alex Aleshin - General Manager Oncology and Chief Medical Officer

Conference Call Participants

Dan Brennan - TD Cowen

Tejas Savant - Morgan Stanley

Puneet Souda - Leerink Partners

Doug Schenkel - Wolfe Research

Catherine Schulte - Baird

Matt Sykes - Goldman Sachs

Presentation

Operator

Thank you for standing by. My name is Greg, and I will be your conference operator today. At this time, I would like to welcome everyone to the Natera Inc. Q1 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]

I would now like to turn the call over to Mike Brophy, Chief Financial Officer. Mike, please go ahead.

Mike Brophy

Thanks, operator. Good afternoon. Thank you for joining our conference call to discuss the results of our first quarter of 2024. On the line, I'm joined by Steve Chapman, our CEO; Solomon Moshkevich, President, Clinical Diagnostics; and Alex Aleshin, General Manager of Oncology and Chief Medical Officer. John Fesko, President and Chief Business Officer is also on the line and will be available for Q&A.

Today's conference call is being broadcast live via webcast. We will be referring to a slide presentation that has been posted to investor.natera.com. A replay of the call will also be posted to our IR site as soon as it's available.

Starting on Slide 2, during the course of this conference call, we will make forward-looking statements regarding future events and our anticipated future performance such as our operational and financial outlook and projections, our assumptions for that outlook, market size partnerships, clinical studies and expected results, opportunities and strategies and expectations for various current and future products including product capabilities, expected release dates, reimbursement coverage and related effects on our financial and operating results.

We caution you that such statements reflect our best judgment based on factors currently known to us and that actual events or results could differ materially. Please refer to the documents we file from time to time with the SEC, including our most recent Form 10-K or 10-Q and the Form 8-K filed with today's press release. Those documents identify important risks and other factors that may cause our actual results to differ materially from those contained or suggested by the forward-looking statements. Forward-looking statements made during the call are being made as of today, May 9, 2024. If this call is replayed or reviewed after today, the information presented during the call may not contain current or accurate information. Natera disclaims any obligation to update or revise any forward-looking statements.

We will provide guidance on today's call, but will not provide any further guidance or updates on our performance during the quarter unless we do so in a public forum. We will quote a number of numerical growth changes as we discuss our financial performance. And unless otherwise noted, each such reference represents a year-on-year comparison....

For further details see: